This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive 
urothelial bladder cancer, as substantial revisions were made in the 2017 
updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, 
durvalumab, and avelumab. The complete version of the NCCN Guidelines for 
Bladder Cancer addresses additional aspects of the management of bladder cancer, 
including non-muscle-invasive urothelial bladder cancer and nonurothelial 
histologies, as well as staging, evaluation, and follow-up.